ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells

Lin, Shouheng; Zhang, Xuchao; Huang, Guohua; Cheng, Lin; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Li, Baiheng; Wei, Wei; Liu, Pentao; Pei, Duanqing; Li, Yangqiu; Wen, Zhesheng; Cui, Shuzhong; Li, Peng; Sun, Xiaofang*; Wu, Yilong*; Yao, Yao*广州医学院; 南方医科大学; 中山大学; 中国科学院; y
Oncogene2021-2-25DOI: 10.1038/s41388-020-01605-4
33被引6阅读
引用收藏
分享

摘要

Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Intratumoral MDSCs directly promoted NSCLC metastasis and highly expressed chemokines that promote NSCLC cells invasion, including CCL11. CCL11 was capable of activating the AKT and ERK signaling pathways to promote NSCLC metastasis through the epithelial-mesenchymal transition (EMT) process. Moreover, high expression of CCL11 was associated with a poor prognosis in lung cancer as well as other types of cancer. Our findings underscore that MDSCs produce CCL11 to promote NSCLC metastasis via activation of ERK and AKT signaling and induction of EMT, suggesting that the MDSCs-CCL11-ERK/AKT-EMT axis contains potential targets for NSCLC metastasis treatment.

学科与关键词

关键词
CORRELATEEOTAXIN-1MICROENVIRONMENTEXPRESSIONPATHWAYSMARKERSTAGE
相关
加载中…
  • Inhibition of CCL7 derived from Mo-MDSCs prevents metastatic progression from latency in colorectal cancer
    Ren, Xiaoli; Xiao, Jianbiao; Zhang, Wanning; Wang, Feifei; Yan, Yongrong; Wu, Xuehui; Zeng, Zhicheng; He, Yumei; Yang, Wei; Liao, Wangjun; Ding, Yanqing; Liang, Li*Cell Death & Disease, 2021, 12(5): 484.被引 15
  • Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy
    Li, Xueyan; Zhong, Jiahui; Deng, Xue; Guo, Xuan; Lu, Yantong; Lin, Juze; Huang, Xuhui*; Wang, Changjun*Frontiers in Immunology, 2021, 12: 754196.被引 13
  • Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway
    Chen, Bonan; Song, Yue; Zhan, Yujuan; Zhou, Shikun; Ke, Junzi; Ao, Weizhen; Zhang, Yigan; Liang, Qiqi; He, Minhui; Li, Shuhui; Xie, Fuda; Huang, Haonan; Chan, Wai Nok; Cheung, Alvin H. K.; Ma, Brigette B. Y.; Kang, Wei; To, Ka Fai*; Xiao, Jianyong*Cancer Letters, 2022, 543: 215783.被引 19
查看全部 →

发表信息

论文状态
公开发表
期刊
Oncogene
发表日期
2021-02-25
卷期
第 40 卷, 第 8 期
页码
1476-1489
DOI
10.1038/s41388-020-01605-4
语言
ENGLISH
期刊收录
NSL
期刊等级
1区
成果收录
SCIE
资助标注
Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19030205]; National Key Research and Development Plan [2017YFE0131600, 2019YFA0111500]; National Natural Science Foundation of China [81961128003, 81972672, 31872800, 81773301, 82003054]; China Postdoctoral Science Foundation [2018M640771]; Guangdong Provincial Significant New Drugs Development [2019B020202003]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110084, 2019A1515010062, 2020A1515011516]; Guangdong Special Support Program [2017TX04R102]; Science and Technology Planning Project of Guangdong Province [2017B030314056]; Natural Science Foundation of Guangdong Province [2020A0505100062]; Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; Guangzhou City Science and Technology Key Topics Project [201904020025]; Guangzhou Science and Technology Plan Project [201907010042, 201904010473]; Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project [201803040009]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program [2018GZR110105003]; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201002]; Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine [2019YF001]; Science and Technology Program of Guangzhou [202002020083]

作者

  • L

    Lin, Shouheng (第一作者)

    guangzhou med univ · chinese acad sci · guangzhou inst biomed & hlth

  • Z

    Zhang, Xuchao

查看全部 21 位作者收起作者
  • H

    Huang, Guohua

    southern med univ

  • C

    Cheng, Lin

    chinese acad sci · guangzhou inst biomed & hlth

  • L

    Lv, Jiang

    chinese acad sci · guangzhou inst biomed & hlth

  • Z

    Zheng, Diwei

    chinese acad sci · guangzhou inst biomed & hlth

  • L

    Lin, Simiao

    chinese acad sci · guangzhou inst biomed & hlth

  • W

    Wang, Suna

    chinese acad sci · guangzhou inst biomed & hlth

  • W

    Wu, Qiting

    chinese acad sci · guangzhou inst biomed & hlth

  • L

    Long, Youguo

    chinese acad sci · guangzhou inst biomed & hlth

  • L

    Li, Baiheng

  • W

    Wei, Wei

  • L

    Liu, Pentao

    univ hong kong

  • P

    Pei, Duanqing

    chinese acad sci · guangzhou inst biomed & hlth

  • L

    Li, Yangqiu

  • W

    Wen, Zhesheng

    sun yat sen univ

  • C

    Cui, Shuzhong

    guangzhou med univ

  • L

    Li, Peng

    chinese acad sci · guangzhou inst biomed & hlth

  • S

    Sun, Xiaofang (通讯)

    guangzhou med univ

  • W

    Wu, Yilong (通讯)

  • Y

    Yao, Yao (通讯)

    chinese acad sci · guangzhou inst biomed & hlth

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417